-
RegMed XB is a translational product development platform that brings together Dutch and Flemish public and private stakeholders to accelerate the development of innovative regenerative therapies.
Infrastructure: RegMed XB's Pilot Factory
A seamless pathway for innovators to accelerate, de-risk, and scale regenerative therapies
read more
-
Phlox Therapeutics, is developing RNA-based therapies for genetic cardiomyopathies
Phlox Therapeutics, is developing RNA-based therapies for genetic cardiomyopathies. Founded by Prof. Dr. Eva van Rooij and Prof. Dr. Yigal Pinto in 2022, the company has made significant progress with Dr. Margien Boels, PhD, as Chief Operating Officer.
read more
RegMed XB is awarded to be one of the selected programs by Health~Holland
In October last year, RegMed XB applied for a 3-year Public-Private Partnership (PPS) subsidy program, called 'Regenerative Medicine Translational Synergy'.
read more
2024 in Review: RegMed XB Highlights
As 2025 has started, we are sharing a look back with the RegMed XB Highlights 2024.
read more -
Moonshots (research excellence)
-
Pilot Factory (infrastructure)
The RegMed XB Pilot Factory is one of the largest international infrastructures for regenerative medicine. It brings together all the expertise and infrastructure needed to bring regenerative medicine to the market.
-
RegMed XB's Ecosystem
Health Foundations
The following Dutch health foundations are involved in defining research objectives and provide guidance in the research we conduct to ensure we maintain focus on the patient.
read moreAcademic Partners
RegMed XB works together with (inter)national top-rated academic institutions and collaborates specifically and exclusively with researchers who contribute specific expertise to the Moonshot initiatives.
read moreIndustrial Partners
Partnering with companies offers access to their expertise in designing scalable and feasible products. Currently, we have strong partnerships with the following entities.
read moreGovernmental Partners
RegMed XB receives support from national and local governments to de-risk promising concepts from academia to proof of concept or initial clinical trial stages.
read more -
-
-
-
-
-
-